AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC.

AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved overall survival (OS), a secondary endpoint, in the

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers